Clinical Research Directory

Inclusion Criteria: * Adults * Individuals greater than or equal to 18 years of age. * Individuals with "Li Fraumeni Syndrome" defined as one of the following: * Carriers of a germline p53 mutation * Members of families meeting classic LFS criteria by family history without an identifiable p53 mutation * Obligate carrier by pedigree (these individuals can be offered testing but are still eligible if they defer). The following examples describe "obligate carriers by pedigree." * A child of a parent with known p53 mutation that is diagnosed with cancer * An individual with a sibling and a child who are p53 positive -OR- * Individuals with an inherited cancer predisposition syndrome as defined by one of the following: * Hereditary Retinoblastoma with a germline Rb mutation * Diagnosis of Hereditary Paraganglioma/Pheochromocytoma Syndrome with a germline SDH mutation * Diagnosis of Multiple Endocrine Neoplasia, Type 1 or 2, with a germline MEN mutation * New diagnosis of opsoclonus-myoclonus with a negative cancer work-up upon presentation of symptoms * Familial Neuroblastoma with a germline ALK mutation * Rapid-onset Obesity with Hypothalamic dysfunction, Hypoventilation and Autonomic Dysregulation (ROHHAD syndrome) or Congenital central hypoventilation syndrome (CCHS) with or without a germline PHOX 2B mutation * Von Hippel-Lindau with a VHL mutation * Women with an abnormal cell-free DNA test (i.e. a non-invasive prenatal test (NIPT) to detect chromosomal abnormalities) and no cancer diagnosis * Other rare cancer predisposition syndromes at the discretion of the treating physician and study physicians * NOTE: Individuals with any of the above-listed cancer predisposition syndromes (apart from Li Fraumeni syndrome) are likewise eligible in the absence of a known mutation if they are an obligate carrier by pedigree. * Individuals can have a prior history of cancer; these individuals must be in stable remission and at least 6 months out from the completion of surgery/radiation\\ therapy/chemotherapy. * Individual cases can be reviewed with the institutional principal investigator. * Individuals not pregnant at enrollment. Female subjects of childbearing potential will undergo a pregnancy test prior to imaging. * Individuals able to give informed consent or a signature from a designated health care proxy or legal guardian. Children * Individuals who are less than 18 years of age * Individuals with "Li Fraumeni Syndrome" defined as one of the following: * Carriers of a germline p53 mutation OR * Members of families meeting classic LFS criteria by family history without an identifiable p53 mutation OR * Obligate carrier by pedigree (these individuals can be offered testing but are still eligible if they defer). The following examples describe "obligate carriers by pedigree." * A child of a parent with known p53 mutation that is diagnosed with cancer * An individual with a sibling and a child who are p53 positive -OR- * Individuals with an inherited cancer predisposition syndrome as defined by one of the following: * Hereditary Retinoblastoma with a germline Rb mutation * Diagnosis of Hereditary Paraganglioma/Pheochromocytoma Syndrome with a germline SDH mutation * Diagnosis of Multiple Endocrine Neoplasia, Type 1 or 2, with a germline MEN mutation * New diagnosis of opsoclonus-myoclonus with a negative cancer work-up upon presentation of symptoms * Familial Neuroblastoma with a germline ALK mutation * Rapid-onset Obesity with Hypothalamic dysfunction, Hypoventilation and Autonomic Dysregulation (ROHHAD syndrome) or Congenital central hypoventilation syndrome (CCHS) with or without a germline PHOX 2B mutation * Von Hippel-Lindau with a VHL mutation * Other rare cancer predisposition syndrome at the discretion of the treating physician and study physicians * NOTE: Individuals with any of the above-listed cancer predisposition syndromes (apart from Li Fraumeni syndrome) are likewise eligible in the absence of a known mutation if they are an obligate carrier by pedigree. * Individuals can have a prior history of cancer; these individuals must be in stable remission and at least 6 months out from the completion of surgery/radiation therapy/chemotherapy. Individual cases can be reviewed with the institutional principal investigator. * Individuals not pregnant at enrollment. Female subjects of childbearing potential will undergo a pregnancy test prior to imaging. * Signed document of informed consent completed by the parent or legal guardian * Signed document of assent obtained if child ≥10 years of age Exclusion Criteria: Adults and Children * Active cancer or metastatic disease, except in the case of Stage 0 Chronic Lymphocytic Leukemia or nonmelanoma skin cancer. * Patients with a contraindication to sedation or general anesthesia * Patients with a metal heart valve, surgical clips, a pacemaker or any other indwelling metal device that might interfere with MRI * Females who are pregnant or nursing